ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

roche registration gmbh - mykofenolát mofetil - odmietnutie štepu - imunosupresíva - cellcept je indikovaný v kombinácii s cyklosporínom a kortikosteroidmi na prevenciu akútneho transplantátu u pacientov užívajúcich alogénnej transplantácii obličiek, srdca alebo pečene.

ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplazmy prsníkov - antineoplastické činidlá - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - amoxicilín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited - omeprazol - 09 - antacida (vrÁtane antiulcerosnych lieČiv)

ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

astrazeneca ab - olaparib - ovariálne nádory - antineoplastické činidlá - ovariálnych cancerlynparza je označené ako monotherapy pre:udržiavaciu liečbu dospelých pacientov s pokročilým (figo fázy iii a iv) brca1/2-zmutoval (germline a/alebo somatických) high-grade epitelové vaječníkov, fallopian trubice alebo primárne peritoneal rakovine, ktorí sú v reakcii (úplné alebo čiastočné) po ukončení prvej línie platinum-založené chemoterapia. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 a 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacienti by mali mať predtým liečení anthracycline a taxane v (neo)adjuvantnej alebo metastatickým nastavenie pokiaľ pacienti neboli vhodné pre tieto liečby (pozri časť 5. u pacientov s hormonálny receptor (hr)-pozitívnou rakovinou prsníka, by tiež mali mať postupoval alebo po pred žliaz s vnútornou sekréciou, terapie, alebo byť považované za nevhodné pre žliaz s vnútornou sekréciou, terapia. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novartis slovakia s.r.o., slovensko - letrozol - 44 - cytostatica

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - letrozol - 44 - cytostatica

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - letrozol - 44 - cytostatica

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

actavis group ptc ehf., island - letrozol - 44 - cytostatica

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vipharm s.a., poľsko - letrozol - 44 - cytostatica